Ozurdex
NICE signs-off Roche’s Gazyvaro for leukaemia
June 2, 2015Sales and Marketing Allergan, Bayer, CLL, Carole Longson, Eylea, Gazyvaro, NICE, Ozurdex, Roche, diabetic macular edema, leukaemia
NICE has given positive final guidance backing the use of Roche’s Gazyvaro for people with chronic lymphocytic leukaemia (CLL). Earlier …
Sue NHS to ensure access to drugs, says NICE chief
August 6, 2012Lucentis, NICE, Ozurdex, judicial review, market access, ophthamology
The chairman of NICE is advising campaigners to sue NHS bodies that block a treatment recommended by the watchdog.In a …
Lucentis not backed by NICE for new licence
November 24, 2011Sales and Marketing Lucentis, NICE, Novartis, Ozurdex
NICE has not recommended Novartis’ eye disease drug Lucentis due to ‘gaps and uncertainties’ in the manufacturer’s submission. In draft …
NICE thumbs up for Allergan’s Ozurdex
June 9, 2011Sales and Marketing Allergan, BRVO, CVRO, NICE, Ozurdex
In draft guidance NICE has recommended the use of Allergan’s eye treatment Ozurdex.NICE’s final decision on Ozurdex (dexamethasone) is expected …
European green light for Allergan’s Ozurdex
May 25, 2010Sales and Marketing Allergan, CHMP, Ozurdex, macular oedema
European authorities have given the green light for Ozurdex, a treatment for adults with a potentially serious eye disease. Ozurdex …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
